摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4R)-4-[(3S,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-二羟基-10,13-二甲基-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊二烯并[a]菲-17-基]戊酸 | 566-24-5

中文名称
(4R)-4-[(3S,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-二羟基-10,13-二甲基-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊二烯并[a]菲-17-基]戊酸
中文别名
熊去氧胆酸杂质K
英文名称
3β,7α-dihydroxy-5β-cholan-24-oic acid
英文别名
3β,7α-isochenodeoxycholic acid;3β,7α-dihydroxycholanic acid;Chenodeoxycholic acid;iso-chenodeoxycholic acid;iso-CDCA;3beta,7alpha-Dihydroxy-5beta-cholan-24-oic Acid;(4R)-4-[(3S,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
(4R)-4-[(3S,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-二羟基-10,13-二甲基-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊二烯并[a]菲-17-基]戊酸化学式
CAS
566-24-5
化学式
C24H40O4
mdl
——
分子量
392.579
InChiKey
RUDATBOHQWOJDD-JGFDLHJZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >190°C (dec.)
  • 沸点:
    547.1±25.0 °C(Predicted)
  • 密度:
    1.128±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于乙腈(略微加热)、甲醇(略微加热)
  • 物理描述:
    Solid

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.96
  • 拓扑面积:
    77.8
  • 氢给体数:
    3
  • 氢受体数:
    4

SDS

SDS:944c900bbcfe7011faa5665ebbc3c74d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Method for normalization in metabolomics analysis methods with endogenous reference metabolites
    申请人:BIOCRATES Life Sciences AG
    公开号:EP2270699A1
    公开(公告)日:2011-01-05
    The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.
    本发明涉及内源参比代谢物的使用以及对哺乳动物受试者生物样本中选定目标代谢物的量和/或浓度对应的强度数据进行归一化的方法,其中所述强度数据是通过一种或多种内源参比代谢物的代谢组学分析方法获得的、包括对所述生物样本中的所述选定目标代谢物进行至少一种体外代谢组学分析方法,同时对同一样本中的一种或多种内源性参考代谢物或其衍生物进行定量分析,其中所述内源性参考代谢物是生物样本中的化合物,它们以基本恒定的水平存在于受试者体内;所述内源性参考代谢物或其衍生物的分子质量小于 1500 Da。
  • High Enantioselective and Large-Scale Production of Ursodeoxycholic Acid by Combination of Pd- and Hydroxysteroid Dehydrogenase-Catalyzed Hydrogenation
    作者:Chunling Zeng、Xirong Liu、Chao Sun、Xinhua Xu、Lifen Peng
    DOI:10.1021/acs.oprd.4c00057
    日期:2024.4.19
    Ursodeoxycholic acid (UDCA) was synthesized from commercially available phytosterol-derived bisnoralcohol with an overall yield of 57% by a six-step process. The absolute configuration of the 3,5,7-stereogenic centers in UDCA was determined using Pd-catalyzed and hydroxysteroid dehydrogenase (HSDH)-catalyzed hydrogenation conducted under normal temperature and atmospheric pressure conditions. To investigate
    熊去氧胆酸(UDCA)是由市售的植物甾醇衍生的双纳尔醇通过六步工艺合成的,总产率为 57%。 UDCA 中 3,5,7-立体中心的绝对构型是通过在常温常压条件下进行的 Pd 催化和羟基类固醇脱氢酶 (HSDH) 催化的氢化来确定的。为了研究催化剂的立体选择性和区域选择性并评估产品的最终纯度,使用带电气溶胶检测 (CAD) 的 HPLC 合成并分析了所有潜在杂质。开发的工艺证明了成本效益以及大规模生产具有 ICH 级质量的 UDCA 的适用性。我们的 Pd 催化和 HSDH 催化氢化技术也可应用于 alphaxalone 和 brexanolone 的合成。
  • EP1985621
    申请人:——
    公开号:——
    公开(公告)日:——
  • Potential bile acid metabolites. 6. Stereoisomeric 3,7-dihydroxy-5.beta.-cholanic acids
    作者:Takashi Iida、Frederic C. Chang
    DOI:10.1021/jo00136a030
    日期:1982.7
  • Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands
    作者:Carmen Festa、Barbara Renga、Claudio D’Amore、Valentina Sepe、Claudia Finamore、Simona De Marino、Adriana Carino、Sabrina Cipriani、Maria Chiara Monti、Angela Zampella、Stefano Fiorucci
    DOI:10.1021/jm501273r
    日期:2014.10.23
    Nuclear and G-protein coupled receptors are considered major targets for drug discovery. FXR and GP-BAR1, two bile acid-activated receptors, have gained increasing consideration as druggable receptors. Because endogenous bile acids often target both receptor families, the development of selective ligands has been proven difficult, exposing patients to side effects linked to an unwanted activation of one of the two receptors. In the present study, we describe a novel library of semisynthetic bile acid derivatives obtained by modifications on the cholane scaffold. The pharmacological characterization of this library led to the discovery of 7a-hydroxy-5 beta-cholan-24-sulfate (7), 6 beta-ethyl-3a,7 beta-dihydroxy-5 beta-cholan-24-ol (EUDCOH, 26), and 6a-ethyl-3a, 7a-dihydroxy-24-nor-5 beta-cholan-23-ol (NorECDCOH, 30) as novel ligands for FXR and GP-BAR1 that might hold utility in the treatment of FXR and GP-BAR1 mediated disorders.
查看更多